Copyright
©The Author(s) 2017.
World J Hepatol. Jan 18, 2017; 9(2): 91-98
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.91
Published online Jan 18, 2017. doi: 10.4254/wjh.v9.i2.91
Table 1 Clinical characteristics of the study population
Variable | n1 | Mean ± SD |
Age (yr) | 77 | 42.4 ± 12.98 |
Gender (male) % | 77 | 46.8 |
BMI (kg/m2) | 77 | 41.71 ± 4.68 |
Glucose (mg/dL) (< 100) | 48 | 116.81 ± 35.08 |
Total cholesterol (mg/dL) (< 200) | 42 | 191.97 ± 34.46 |
LDL (mg/dL) | 42 | 112.80 ± 33.05 |
HDL (mg/dL) | 40 | 44.19 ± 11.87 |
TG (mg/dL) (< 150) | 42 | 182.38 ± 56.36 |
ALT (U/L) (5-39) | 47 | 44.28 ± 44.49 |
AST (U/L) (7-40) | 47 | 28.91 ± 20.11 |
Success rate % | 77 | 84.31 ± 13.55 |
Stiffness | 77 | 10.24 ± 6.27 |
Sedentary time2 (min/d) | 77 | 263.84 ± 176.56 |
Daily activity (score3) | 77 | 20.56 ± 3.47 |
Alcohol servings/week | 77 | 0.66 ± 1.67 |
Current or past smokers % | 77 | 48.1 |
Table 2 Comparison between subjects with fibrosis degree F < 2 and subjects with significant fibrosis degree F ≥ 2 (mean ± SD, unless otherwise stated)
Variable | F < 2 (n = 31) | F ≥ 2 (n = 46) | P |
Gender (men) % | 22.6 | 63 | < 0.001 |
Age (yr) | 42.32 ± 13.89 | 42.96 ± 12.29 | 0.838 |
Education (yr) | 13.13 ± 2.05 | 13.78 ± 2.9 | 0.281 |
BMI (kg/m2) | 39.82 ± 3.16 | 42.99 ± 5.11 | < 0.001 |
Type 2 diabetes drugs (%) | 19.4 | 17.4 | 0.827 |
All sugared soft drinks (cups/d) | 1.76 ± 2.74 | 1.38 ± 2.24 | 0.502 |
Carbonated sugared drinks intake (cups/d) | 0.99 ± 1.52 | 0.89 ± 1.98 | 0.816 |
Diet carbonated drinks intake (cups/d) | 0.46 ± 0.98 | 0.88 ± 1.6 | 0.196 |
Coffee intake (cups/d) | 2.22 ± 1.87 | 1.77 ± 1.74 | 0.287 |
Alcohol servings/week | 0.97 ± 1.80 | 0.46 ± 1.56 | 0.189 |
Current or past smokers (%) | 48.4 | 47.8 | 0.961 |
Fruits intake (portions/d) | 1.71 ± 1.35 | 1.74 ± 1.31 | 0.924 |
Vegetables intake (portions/d) | 2.77 ± 2.38 | 2.64 ± 1.93 | 0.788 |
Fried food intake (portions/d) | 1.18 ± 1.25 | 1.08 ± 0.77 | 0.690 |
Leisure time physical activity (min/wk) | 189 ± 83.06 | 237.69 ± 437.89 | 0.733 |
Sedentary time1 (min/d) | 264.19 ± 171.7 | 263.61 ± 181.65 | 0.989 |
Daily activity (score2) | 20.19 ± 2.83 | 20.8 ± 3.85 | 0.452 |
Glucose (mg/dL) | 113.72 ± 42.35 | 119.42 ± 28.13 | 0.580 |
Total cholesterol (mg/dL) | 202.68 ± 37.79 | 182.24 ± 28.6 | 0.054 |
LDL (mg/dL) | 121.52 ± 38.77 | 104.04 ± 23.97 | 0.088 |
HDL (mg/dL) | 46.55 ± 11.42 | 41.83 ± 12.13 | 0.213 |
Triglycerides (mg/dL) | 170.73 ± 60.25 | 192 ± 52.3 | 0.228 |
ALT (U/L) | 34.89 ± 37.77 | 50.66 ± 48.13 | 0.237 |
AST (U/L) | 26.4 ± 24.47 | 30.78 ± 16.43 | 0.467 |
GGT (U/L) | 22.52 ± 12.01 | 43.06 ± 23.53 | 0.090 |
Table 3 Comparison between subjects with fibrosis degree F < 3 and subjects with advanced fibrosis degree F ≥ 3 (mean ± SD, unless otherwise stated)
Variable | F < 3 (n = 47) | F ≥ 3 (n = 30) | P |
Gender (male) % | 36.2 | 63.3 | 0.020 |
Age (yr) | 42.47 ± 14 | 43.07 ± 11.09 | 0.836 |
Education (yr) | 13.19 ± 2.59 | 14.03 ± 2.55 | 0.166 |
BMI (kg/m2) | 40.68 ± 3.96 | 42.32 ± 5.3 | 0.023 |
Type 2 diabetes drugs (%) | 17 | 20 | 0.741 |
All sugared soft drinks (cups/d) | 1.64 ± 2.45 | 1.37 ± 2.46 | 0.635 |
Carbonated sugared drinks intake (cups/d) | 0.9 ± 1.55 | 0.98 ± 2.16 | 0.850 |
Diet carbonated drinks intake (cups/d) | 0.73 ± 1.44 | 0.68 ± 1.33 | 0.890 |
Coffee intake (cups/d) | 1.96 ± 1.88 | 1.93 ± 1.69 | 0.951 |
Alcohol (servings/wk) | 0.87 ± 1.76 | 0.33 ± 1.47 | 0.152 |
Current or past smokers (%) | 48.9 | 46.7 | 0.846 |
Fruits intake (portions/d) | 1.57 ± 1.25 | 1.97 ± 1.4 | 0.204 |
Vegetables intake (portions/d) | 2.43 ± 2.11 | 3.12 ± 2.07 | 0.162 |
Fried food intake (portions/d) | 1.12 ± 1.12 | 1.12 ± 0.75 | 0.999 |
Leisure time physical activity (min/wk) | 155.62 ± 89.96 | 355.71 ± 585.97 | 0.403 |
Sedentary time1 (min/d) | 265.66 ± 178.79 | 261.00 ± 176.01 | 0.911 |
Daily activity (score2) | 20.32 ± 3.49 | 20.93 ± 3.45 | 0.452 |
Glucose (mg/dL) | 117 ± 39.93 | 116.53 ± 27.08 | 0.964 |
Total cholesterol (mg/dL) | 197.75 ± 37.39 | 180.41 ± 25 | 0.083 |
LDL (mg/dL) | 117.81 ± 35.94 | 101.61 ± 22.00 | 0.087 |
HDL (mg/dL) | 44.85 ± 11.16 | 42.82 ± 13.6 | 0.619 |
Triglycerides (mg/dL) | 176.28 ± 55.14 | 194.57 ± 58.84 | 0.328 |
ALT (U/L) | 36.5 ± 33.26 | 55.76 ± 56.26 | 0.147 |
AST (U/L) | 26.89 ± 21.99 | 31.89 ± 17.11 | 0.409 |
GGT (U/L) | 29.89 ± 26.25 | 43.4 ± 16.96 | 0.241 |
Table 4 Multivariate analysis for the prediction of significant or advanced fibrosis
Variable | Model 1: F ≥ 2 | Model 2: F ≥ 3 | ||
OR (95%CI) | P | OR (95%CI) | P | |
Age (yr) | 1.03 (0.99-1.08) | 0.153 | 1.03 (0.98-1.07) | 0.246 |
Gender (male) | 7.93 (2.36-26.64) | 0.001 | 2.92 (1.08-7.91) | 0.035 |
BMI (kg/m2) | 1.33 (1.11-1.60) | 0.002 | 1.17 (1.03-1.33) | 0.018 |
- Citation: Zelber-Sagi S, Shoham D, Zvibel I, Abu-Abeid S, Shibolet O, Fishman S. Predictors for advanced fibrosis in morbidly obese non-alcoholic fatty liver patients. World J Hepatol 2017; 9(2): 91-98
- URL: https://www.wjgnet.com/1948-5182/full/v9/i2/91.htm
- DOI: https://dx.doi.org/10.4254/wjh.v9.i2.91